Specification
| Reactivities | Human |
| Target | F9xF10 |
| Approved Therapeutic | Emicbio |
| Isotype | Human IgG4 mutation-kappa |
| Property | Bispecific Antibody |
| Alernative Name | ACE-910,ACE910,RG6013,hBS910;coagulation factor 10, coagulation factor X;coagulation factor 9, coagulation factor IX |
| Recommended Isotype | |
| Recommended Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives. |
| Formulation Buffer | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >90% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Expression Host | CHO |
| Purification Method | IEC |
| Storage | 2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
| Note | Due to the variability in applications, investigators should consult application references to estimate the appropriate dose or concentration. This dose or concentration can then be further optimized through experimental methods such as dose-response or titration experiments |
Background
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |